Clinical trial · Observational
Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria
Non-interventional, Multicenter, Prospective Register Study to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer (ROC) Patients in Austria
NCT04369352CI-TRIAL-00065077unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Various treatment options exist for patients with platinum-sensitive relapsed epithelial ovarian cancer (ROC). The register will provide an overview of chosen treatments including the reasons, why these options were chosen.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Ovarian Carcinoma | Ovarian Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To assess treatment patterns and the reasons for selecting these treatments in patients with platinum-sensitive ROC after first relapse in Austria
- timeFrame
- Two years
- description
- Descriptive Data Analysis
Secondary outcomes (4)
- measure
- Progression Free Survival
- timeFrame
- 2 years per patient
- description
- after first relapse and second relapse, evaluated by clinical practice in each center
- measure
- Overall Survival
- timeFrame
- 2 years per patient
- description
- at 24 months
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Women aged 18 years or older * Presence of first platinum-sensitive ROC (ovarian, peritoneal and/or fallopian tube cancer) * Must have received at least 4 cycles of chemotherapy during primary therapy * At time of inclusion a treatment for ROC must be planned * Patients must not have more than 1 prior line of chemotherapy * Signed informed consent Exclusion Criteria: * No knowledge of spoken and written German * Signed informed consent is not given
References
Publications (0)
Data not yet available
No reference posted for this study.